Zanubrutinib
BGB-3111-305
Phase 3 small_molecule completed
Quick answer
Zanubrutinib for Chronic Lymphocytic Leukemia is a Phase 3 program (small_molecule) at BeiGene with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BeiGene
- Indication
- Chronic Lymphocytic Leukemia
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed